Drugs / ECI-006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03394937 | Jun 2017 → Dec 2020 | melanoma | eTheRNA immunotherapies | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECI-006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03394937 ↗ |
| Modality | Messenger RNA (mRNA) | “ECI-006 consists of TriMix and 5 tumor associated antigens mRNA.” NCT03394937 ↗ |
| Route | Other | “ECI-006 will be administered 5 times by intranodal injection in melanoma patients after resection of their tumor.” NCT03394937 ↗ |